Medication info
Newstatin TS Tablet 40/5/10 milligrams

Newstatin TS Tablet 40/5/10 milligrams

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Samjin Pharmaceutical Co., Ltd.
Appearance
An oval biconvex bilayer tablet consisting of a white layer and a light blue layer
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201802236 · Approved 2018.05.30 · Insurance code 647804710

Summary

Main use
Improves dyslipidemia, treats hypertension, and inhibits the progression of atherosclerosis and the risk of cardiovascular disease
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This drug is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients receiving concomitant telmisartan/amlodipine combination therapy and rosuvastatin as a single agent, switching to this drug (a combination product containing the same amount of each active ingredient) may be considered for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose of each individual component (amlodipine or telmisartan) be adjusted. However, if blood pressure is not controlled with an individual component, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this drug 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this drug 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, treatment should be initiated at a low dose and the dose increased gradually because amlodipine clearance is reduced. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin 40 mg is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this drug, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, the Cmax of rosuvastatin increased approximately 2.1-fold and its AUC approximately 1.2-fold in the presence of telmisartan/amlodipine. Therefore, when administering this drug, the potential risk due to the increase in rosuvastatin Cmax should be assessed, and patients should be monitored closely.

Ingredients

Manufacturer
Samjin Pharmaceutical Co., Ltd.

Efficacy & effects

Improves dyslipidemia, treats hypertension, and inhibits the progression of atherosclerosis and the risk of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is administered to patients with essential hypertension for whom blood pressure is not sufficiently controlled by monotherapy with Telmisartan and Amlodipine, and is used when Rosuvastatin needs to be taken concurrently. The Telmisartan/Amlodipine combination effectively controls blood pressure and helps stabilize blood pressure levels. Rosuvastatin serves as an adjunct to the dietary management of hypercholesterolemia and hyperlipidemia, lowering levels of cholesterol and LDL cholesterol in the blood, thus delaying the progression of atherosclerosis. Additionally, it is effective in reducing the risk of stroke or myocardial infarction, and the risk of recurrence after revascularization in patients at high risk for cardiovascular diseases. Therefore, this medication is used to manage both hypertension and dyslipidemia, improving cardiovascular health.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This drug is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients receiving concomitant telmisartan/amlodipine combination therapy and rosuvastatin as a single agent, switching to this drug (a combination product containing the same amount of each active ingredient) may be considered for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose of each individual component (amlodipine or telmisartan) be adjusted. However, if blood pressure is not controlled with an individual component, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this drug 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this drug 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, treatment should be initiated at a low dose and the dose increased gradually because amlodipine clearance is reduced. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin 40 mg is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this drug, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, the Cmax of rosuvastatin increased approximately 2.1-fold and its AUC approximately 1.2-fold in the presence of telmisartan/amlodipine. Therefore, when administering this drug, the potential risk due to the increase in rosuvastatin Cmax should be assessed, and patients should be monitored closely.

Precautions

This medication should not be used during pregnancy. If pregnancy is confirmed, discontinue use immediately, and women of childbearing potential should use appropriate contraception. This medication should not be administered to patients who are allergic to the active ingredients or other components, patients with severe liver or kidney impairment, or those with a history of specific muscle disorders. Patients with very low blood pressure, elderly individuals, patients with hyperkalemia, and those with weakened liver function should use this medication with caution, and it is important to periodically check liver and kidney function before and during treatment. If symptoms such as muscle pain, weakness, or cramps occur, consult a physician immediately, and if necessary, blood tests should be performed to check for muscle damage. This medication may interact with other drugs, so patients should inform healthcare providers about any medications they are currently taking, especially with certain antibiotics, immunosuppressants, and fibrate medications that require caution when combined. Breastfeeding mothers are advised against taking this medication, and if necessary, should discontinue breastfeeding during treatment. Overdosage may lead to low blood pressure, dizziness, cardiac issues, etc.; immediate medical attention is required. Safety and effectiveness in children have not been established, so administration is not recommended. During treatment, there may be dizziness or drowsiness when driving or operating hazardous machinery, so caution is advised.

Side effects

Peripheral edema, dyspepsia, frequent bowel movements, diabetes mellitus, dizziness, dry vesicular sounds, urticaria, unstable angina, onychomycosis, lumbar spinal canal stenosis, ear discharge, vertigo, chronic gastritis, various gastrointestinal disorders, hiatal hernia, dysuria, rhinitis, pharyngeal discomfort, lung diseases, unspecified bowel disease, benign gastric neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory tract infection, low back pain, sinusitis, diarrhea, pharyngitis, influenza-like symptoms, dyspepsia, myalgia, urinary tract infection, abdominal pain, headache, dizziness, pain, fatigue, cough, hypertension, chest pain, nausea, palpitations, dependent edema, angina, rapid pulse, leg edema, abnormal ECG, insomnia, drowsiness, migraine, dizziness, sensory abnormalities, involuntary muscle contractions, sensory loss, flatulence, constipation, gastritis, vomiting, dry mouth, hemorrhoids, gastroenteritis, enteritis, gastroesophageal reflux, toothache, nonspecific gastrointestinal diseases, gout, hypercholesterolemia, diabetes, arthritis, arthralgia, leg numbness, anxiety, depression, irritability, infection, fungal infection, abscess, otitis media, asthma, bronchitis, rhinitis, dyspnea, epistaxis, dermatitis, rash, eczema, pruritus, frequent urination, cystitis, cerebrovascular disease, visual disturbances, conjunctivitis, ear pain, vascular edema, fever, leg pain, malaise, headache, asthenia, cough, nausea, fatigue, weakness, edema, facial swelling, lower limb edema, vascular edema, pruritus, hypersensitivity reactions, increased sweating, erythema, chest pain, atrial fibrillation, congestive heart failure, myocardial infarction, increased blood pressure, worsening hypertension, hypotension, hyperkalemia, hypoglycemia, syncope, low back pain, abdominal pain, muscle cramps, myalgia, bradycardia, eosinophilia, thrombocytopenia, increased uric acid, liver dysfunction, liver disease, acute renal failure, anemia, elevated CPK, anaphylactic reaction, tendon pain, rhabdomyolysis, vasculitis, peripheral neuropathy, tremors, loss of appetite, dysphagia, pancreatitis, gingival hyperplasia, allergic reactions, burning sensation, malaise, rigidity, weight gain, weight loss, sexual dysfunction, insomnia, abnormal dreams, depersonalization, dyspnea, vascular edema, polycyclic erythema, erythematous rash, papular rash, diplopia, eye pain, urinary disorders, nocturia, dry mouth, increased sweating, hyperglycemia, thirst, leukopenia, purpura, thrombocytopenia, heart failure, irregular pulse, ectopic beats, skin depigmentation, skin dryness, hair loss, dermatitis, muscle weakness, single contraction, coordination disorders, excessive muscle tension, cold moist skin, apathy, anxiety, amnesia, gastritis, increased appetite, loose stools, rhinitis, polyuria, abnormal sense of smell, taste disorder, abnormal ocular control, dry eye syndrome, gynecomastia, jaundice, elevated liver enzymes, leukopenia, confusion, exfoliative dermatitis, Stevens-Johnson syndrome, photosensitivity reactions, toxic epidermal necrolysis, headache, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, vascular edema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, vascular edema, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive decline, forgetfulness, amnestic syndrome, memory impairment, confusion, severe myasthenia gravis, ocular myasthenia gravis, hypotension, tachycardia, bradycardia, acute renal failure, excessive peripheral vasodilation, reflex tachycardia, systemic hypotension, shock, non-cardiogenic pulmonary edema, severe hypotension, increased serum potassium and creatinine levels, increased serum creatinine and blood urea nitrogen, intravascular volume depletion, blood volume and sodium depletion, vascular edema, thrombocytopenia, increased serum creatinine, acute renal failure, oliguria, musculoskeletal pain, cerebral infarction, neck pain, nasopharyngitis, upper abdominal discomfort, upper abdominal pain, orthostatic dizziness, effects on skeletal muscle, myalgia, myopathy, rhabdomyolysis, immune-mediated myopathy, muscle weakness, cramps, elevated CK levels, increased ALT, increased AST, asthenia, arthralgia, fatigue, numbness, sensory abnormalities, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, muscle cramps, gout, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that protects it from light. It is also advisable to store it at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the medication's efficacy and safety.

Appearance and packaging

Appearance

An oval biconvex bilayer tablet consisting of a white layer and a light blue layer

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.